Xiamen, China, 24 March, 2020–Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology companion diagnostic (CDx) test based on AmoyDx's industry-leading NGS platform.
Under the terms of the agreement, AmoyDx will develop and pursue National Medical Products Administration (NMPA) approval for the AmoyDx® LC10-Essential NGS Panel, to secure NMPA approval for use as a companion diagnostic for an oncology therapy.
“We are extremely excited to announce this co-development collaboration for the China market” said Li-Mou Zheng, Ph.D., Founder and CEO of AmoyDx. “AmoyDx has strong pipeline of diagnostic products for precision medicines. Using our test to help guide treatment decisions will address a high unmet medical need among patients. AmoyDx is a trusted partner for co-development of companion diagnostic with the integrated capabilities of R&D, Regulatory Affairs and Commercialization.
About Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. (SZSE: 300685) is a leading biotech company which pioneered the development and commercialization of cancer diagnostics in China. It is the largest provider of molecular diagnostics products for personalized healthcare in China, as well as a service center for oncology biomarker analysis. AmoyDx has a market-leading portfolio of molecular tests and is the therapy diagnostics partner for several major multinational pharmaceutical companies offering precision therapies for cancer.